Sivextro

Chemical Nametedizolid phosphate
Dosage FormInjection (intravenous; 200 mg); Tablet (oral; 200 mg)
Drug ClassAntibacterials
SystemSkin
CompanyNabriva Therapeutics
Approval Year2014

Indication

  • For the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
Last updated on 7/18/2022

More on this drug: Clinical Trials

Document TitleYearSource
Sivextro (tedizolid phosphate) Prescribing Information.2021Nabriva Therapeutics US, Inc., Fort Washington, PA

Have we missed a study, or would you like to comment on a study?